Top-News
Professionelle Dienstleistungen Schweiz

Kinarus Therapeutics News

Aktie
WKN:  928449 ISIN:  CH0009115129
Keine aktuellen Kursdaten verfügbar
28.06.19 20:00:00
Handeln Depot/Watchlist
Aktienanzahl *
1,30 Mrd.
Marktkapitalisierung *
22,75 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 11.03.2024

Unternehmensmeldungen

01.03.24 - DGAP
Extraordinary General Meeting of Kinarus Holding approved all resolutions relating to the envisaged Business Combination with Curatis
Kinarus Therapeutics Holding AG / Key word(s): AGMEGM Extraordinary General Meeting of Kinarus Holding approved all resolutions relating to the envisaged Business ...
12.07.23 - DGAP
Kinarus Therapeutics Announces Personnel Changes
Kinarus Therapeutics Holding AG / Key word(s): Personnel Kinarus Therapeutics Announces Personnel Changes 12.07.2023 / 07:00 CET/CEST
12.07.23 - GlobeNewswire
Kinarus Therapeutics Announces Personnel Change
Basel, Switzerland, July 12 , 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-​stage biopharmaceutical company developing novel therapeutics to treat viral, ...
29.06.23 - DGAP
Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting
Kinarus Therapeutics Holding AG / Key word(s): AGMEGM Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting 29.06.2023 / 18:00 ...
29.06.23 - GlobeNewswire
Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting
Basel, Switzerland , 2 9 Jun e 202 3 . Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-​stage biopharmaceutical company developing novel ...
27.06.23 - GlobeNewswire
Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity
Basel, Switzerland, June 26 , 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-​stage biopharmaceutical company developing novel therapeutics to treat viral, ...
02.06.23 - DGAP
Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting
Kinarus Therapeutics Holding AG / Key word(s): AGMEGM Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting 02.06.2023 / 08:00 CET/CEST
02.06.23 - GlobeNewswire
Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting
Basel, Switzerland , 2 Jun e 202 3 . Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-​stage biopharmaceutical company developing novel ...
31.05.23 - GlobeNewswire
Kinarus Therapeutics Group Reports 2022 Annual Results
Publishes Annual Report with Audited Consolidated Financial Results for Year Ended 31 December 2022 Clinical efforts re-​focused on developing KIN001 for original indications ...
11.05.23 - GlobeNewswire
Kinarus Therapeutics signed CHF1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management
Basel, Switzerland, May 10 , 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-​stage biopharmaceutical company developing novel therapeutics to treat viral, ...
05.05.23 - GlobeNewswire
Kinarus Therapeutics Reports Key Unaudited Full Year 2022 Figures
Audited full year 2022 annual financial figures due to be reported by end of May 2023 Basel, Switzerland, May 5, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a ...
28.04.23 - GlobeNewswire
Kinarus Therapeutics Holding AG ("Kinarus") receives deadline extension from SER for publication of its 2022 annual financial report
Ad hoc announcement pursuant to Art. 53 LR Kinarus Therapeutics Holding AG ("Kinarus") receives deadline extension from SER for publication of its 2022 annual financial report ...
21.02.23 - DGAP
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update
Kinarus Therapeutics Holding AG / Key word(s): Research Update/Study Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update 21.02.2023 / 07:00 ...
21.02.23 - GlobeNewswire
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update
KINFAST is evaluating KIN001 for reduc tion in severity and duration of Covid-19 symptoms KINFAST is actively enrolling in Germany/Switzerland Basel, Switzerland, 20 February ...
17.01.23 - DGAP
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
Kinarus Therapeutics Holding AG / Key word(s): Research Update/Study results Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical ...
17.01.23 - GlobeNewswire
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
KIN001 reduced fibrotic damage of the lung in a preclinical fibrosis model P otential as an effective oral therapy for Idiopathic Pulmonary Fibrosis (IPF) Phase 2 clinical trial in IPF ...
06.12.22 - DGAP
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
Kinarus Therapeutics Holding AG / Key word(s): Research Update Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and ...
06.12.22 - GlobeNewswire
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
Kinarus Therapeutics ’ KIN001 Shows Strong A ntiviral Activity A gainst SARS-CoV-2 Omicron Subvariants BA. 2 and BA.5
22.11.22 - DGAP
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
Kinarus Therapeutics Holding AG / Key word(s): Patent Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001 22.11.2022 / 07:00 CET/CEST
22.11.22 - GlobeNewswire
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
M ethod - of - use - patent covers KIN001 in ophthalmic diseases Further strengthen s already granted KIN001 US composition of matter patent Basel, Switzerland, 22 November ...

Newssuche

Videos

29.05.24
Technical Trading: DAX Long Chance kurzfristig
DAX Long Typ: Turbo Open End WKN: VD5FWS Hebel: 28 Laufzeit: OpenEnd Einstieg: Market ... Mehr »